title: Optimal Treatment for Complicated Intra-abdominal Infections in the Era of Antibiotic Resistance: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Therapy With Metronidazole.
abstract: Background.Carbapenem-resistantEnterobacteriaceaehas increased dramatically in the last decade, resulting in infections that are difficult to treat and associated with high mortality rates. To prevent further antibacterial resistance, it is necessary to use carbapenem selectively. A combination of metronidazole with an antimicrobial agent active against aerobes is an alternative effective treatment for patients with complicated intra-abdominal infections (cIAIs). This study aimed to compare efficacy and safety of metronidazole combination therapies and carbapenem and to provide clinical evidence regarding the optimal treatment of cIAI.Methods.A systematic review and a meta-analysis of randomized clinical trials in the treatment of cIAI were conducted. The systematic review with PubMed, Embase, and the Cochrane Database of Systematic Reviews followed the Cochrane Handbook's recommended methodology, and the meta-analysis used a Mantel-Haenszel random-effects model with RevMan, version 5.3. Primary endpoints were clinical success and bacteriological eradication, and secondary endpoints were all-cause mortality and drug-related adverse events.Results.Eight studies comparing metronidazole combination therapies and carbapenem were included in the meta-analysis. No difference was found between combined therapy with metronidazole and carbapenem regarding clinical success (odds ratio [OR] = 1.31; 95% confidence interval [CI], .75-2.31), bacteriological eradication (OR = 1.27; 95% CI, .84-1.91), all-cause mortality (OR = 0.61; 95% CI, .37-1.00), or drug-related adverse events (OR = 0.58; 95% CI, .18-1.88). Sensitivity analyses found similar results.Conclusions.Combined therapy with metronidazole is as effective and safe as carbapenem in treatment of cIAI. Therefore, combined therapy with metronidazole offers an effective alternative to carbapenem with low risk of drug resistance.
authors.affiliation: Department of Clinical Infectious Diseases , Aichi Medical University Graduate School of Medicine , Nagakute.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Mikamo
authors.affiliation: Medical Affairs Department , Pfizer Japan Inc.
authors.forename: Akira
authors.initials: A
authors.lastname: Yuasa
authors.affiliation: Real-World Evidence Solutions and Health Economics and Outcomes Research, IMS Japan K.K. , Tokyo.
authors.forename: Keiko
authors.initials: K
authors.lastname: Wada
authors.affiliation: Real-World Evidence Solutions and Health Economics and Outcomes Research, IMS Japan K.K. , Tokyo.
authors.forename: Bruce
authors.initials: B
authors.lastname: Crawford
authors.affiliation: Medical Affairs Department , Pfizer Japan Inc.
authors.forename: Naomi
authors.initials: N
authors.lastname: Sugimoto
keywords: CRE; carbapenem-resistant Enterobacteriaceae; complicated intra-abdominal infection; meta-analysis; metronidazole